We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Skinbiotherapeutics Plc | LSE:SBTX | London | Ordinary Share | GB00BF33H870 | ORD 1P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 9.25 | 9.00 | 9.50 | 9.25 | 9.25 | 9.25 | 236,233 | 07:44:03 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Biological Pds,ex Diagnstics | 132k | -2.84M | -0.0163 | -5.67 | 16.1M |
Date | Subject | Author | Discuss |
---|---|---|---|
19/7/2018 16:16 | Nobby - see reply. Good to chat. | elrico | |
19/7/2018 15:58 | >>elrico I have sent you a PM.... | nobbygnome | |
19/7/2018 15:36 | Nobby - With due respect, you and I know there are many reasons for a funding. Larva is suggesting a bailout placing. If I'm misrepresenting larva's comment, then I have afforded the opportunity to correct, thus far, no correction. OPTI took the opportunity to which the company had already issued a caveat to, and one I also flagged as the only reasons for a placing. OPTI's funding was to expedite a commercial opportunity they ran the risk of losing, the placing wasn't to keep the lights on, as our friend Michellemouse implied. The end result, pharma LP-LDL will be c12-18 months away, not several years. | elrico | |
19/7/2018 14:06 | >> elrico With all due respect it is dangerous to ask questions about fund raisings. Before the latest OPTI raise, you would have said they didn't need any more cash. But raise money they did.... | nobbygnome | |
19/7/2018 14:01 | lol larva, you must related to michaelmouse | slartybartfaster | |
19/7/2018 13:24 | larva - out of interest, how much cash is left and how long do you expect it to last? I guess here endeth the debate, as I don't expect you to answer either of those BASIC questions. | elrico | |
19/7/2018 13:00 | Not much cash left Placing at 5p? | larva | |
19/7/2018 12:54 | yes i've just had a little top up after those couple of sells just snicked the price down a little. Opti is powering on nicely as well today..very pleased indeed. | belgrano2 | |
19/7/2018 09:03 | Potential here is huge. share price ticked up again this morning on the back of a single buy order. | rathean | |
19/7/2018 08:49 | Novartis paying 95m Euros to Galapagos for psoriasis drug? | semper vigilans | |
18/7/2018 14:18 | Looks like I might have jinxed it, back to your original time frame :) | rathean | |
18/7/2018 09:00 | Rathean - In my thinking I must confess to forgetting September was a month in the year...;) | elrico | |
18/7/2018 08:17 | We might see Elrico's 20p+ sooner than expected :) | rathean | |
18/7/2018 08:10 | All on track and a good start this morning, nice. | rafboy | |
18/7/2018 08:01 | Another small hurdle successfully negotiated this morning with the process for the tests in September being approved. | wreckage | |
17/7/2018 22:11 | Elric, an excellent write up. Thank you. | rafboy | |
17/7/2018 15:35 | Are we going to have some news here very soon? Volume good and share price increasing, what’s not to like! | rafboy | |
17/7/2018 15:04 | Big brother’s moving north look’s like little brother is following him. | warren1982 | |
17/7/2018 14:48 | Can't get a quote through HL, will sit on my stash and see where this goes :) | rathean | |
17/7/2018 14:19 | I was only able to grab 6500 and that was 7% premium to when i put the order in. | incanus | |
17/7/2018 14:05 | Riding on the back of Opti too? Surely buyers will come in during the lead up to the trial? | deeppockets | |
17/7/2018 14:03 | Price action indicates that the seller has cleared and now limited supply, added some more. | matt123d | |
17/7/2018 13:09 | No volume here and couldn't get an online quote for 5k. | incanus |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions